Silence Therapeutics (SLN) Invested Capital (2018 - 2025)
Silence Therapeutics' Invested Capital history spans 8 years, with the latest figure at $62.3 million for Q4 2025.
- On a quarterly basis, Invested Capital fell 53.51% to $62.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.3 million, a 53.51% decrease, with the full-year FY2025 number at $62.3 million, down 53.51% from a year prior.
- Invested Capital hit $62.3 million in Q4 2025 for Silence Therapeutics, down from $74.1 million in the prior quarter.
- Over the last five years, Invested Capital for SLN hit a ceiling of $156.8 million in Q1 2024 and a floor of $11.5 million in Q4 2021.
- Historically, Invested Capital has averaged $76.8 million across 5 years, with a median of $74.1 million in 2025.
- Biggest five-year swings in Invested Capital: skyrocketed 825.94% in 2024 and later plummeted 53.51% in 2025.
- Tracing SLN's Invested Capital over 5 years: stood at $11.5 million in 2021, then skyrocketed by 125.26% to $25.9 million in 2022, then decreased by 18.26% to $21.2 million in 2023, then skyrocketed by 533.33% to $134.0 million in 2024, then plummeted by 53.51% to $62.3 million in 2025.
- Business Quant data shows Invested Capital for SLN at $62.3 million in Q4 2025, $74.1 million in Q3 2025, and $94.2 million in Q2 2025.